Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.

Tracey WeissRichard D CarrSampriti PalLingfeng YangBaanie Sawhney Robert L BoggsSwapnil RajpathakKristy Iglay

Published in: Patient preference and adherence (2020)

Over half of T2DM patients initiating GLP-1 RA were non-adherent and the majority (70.1%) discontinued therapy by 24 months. Reasons for non-adherence and discontinuation merit further research.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
type diabetes
mesenchymal stem cells
metabolic syndrome
systemic sclerosis
idiopathic pulmonary fibrosis